greenyellow personal page - To The Moon

greenyellow

greenyellow

No personal profile

31Follow

1Followers

0Topic

0Badge

2021-08-17

buy the dip

Sorry, the original content has been removed

2021-08-11

baidu ??

Sorry, the original content has been removed

2021-08-11

good read

Sorry, the original content has been removed

2021-08-09

insane gain rate

Sorry, the original content has been removed

2021-08-06

like

Sorry, the original content has been removed

2021-08-06

good

Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer

2021-08-06

good

Sorry, the original content has been removed

2021-08-05

Chinese EV will still be the dominant player in China

Sorry, the original content has been removed

2021-08-04

informative

Sorry, the original content has been removed

2021-06-18

good recommendation

Next Market Crash: 2 Top Growth Stocks to Buy Right Now

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586352028840306","uuid":"3586352028840306","gmtCreate":1623258977373,"gmtModify":1624026421052,"name":"greenyellow","pinyin":"greenyellow","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":31,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"4e86300037264823b9bb00ff44fc0f19-6","templateUuid":"4e86300037264823b9bb00ff44fc0f19","name":"Live trading challenger","description":"for 12 months","bigImgUrl":"https://community-static.tradeup.com/news/b76669c276447115bf9cde881b0cba68","smallImgUrl":"https://community-static.tradeup.com/news/6d5ffd25685d045ade4bb948ef8fd5c3","grayImgUrl":"https://community-static.tradeup.com/news/076cd4597f6ea22aabdd4f6a12b2c293","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5600},{"badgeId":"f8545949683242faa8dd0b48c38980be-5","templateUuid":"f8545949683242faa8dd0b48c38980be","name":"Monthly top 10 team’s member","description":"Top 10","bigImgUrl":"https://community-static.tradeup.com/news/dcb8ba4e1efd99be2b948dc3b81abfa8","smallImgUrl":"https://community-static.tradeup.com/news/a4aa0d1bc9d709e9af2662788ca5d144","grayImgUrl":"https://community-static.tradeup.com/news/5704f3dcb758b5392763b7709ebf548a","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5400},{"badgeId":"e93d6aec3f8541a685bf0bdf8480c06e-1","templateUuid":"e93d6aec3f8541a685bf0bdf8480c06e","name":"Ace trader","description":"Top 100","bigImgUrl":"https://community-static.tradeup.com/news/556b13e675ec6fa1a877ec0c9860c5f0","smallImgUrl":"https://community-static.tradeup.com/news/177968b7619e5233f005572817da5e36","grayImgUrl":"https://community-static.tradeup.com/news/163c3f461f45a3bde3077a7179194a5a","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5500},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"23f878ed27704312ae41c7f17e73b319-3","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 20%","bigImgUrl":"https://community-static.tradeup.com/news/1ece4391160b811e6f36b1eea9eb6ea4","smallImgUrl":"https://community-static.tradeup.com/news/7d7540817554a583ac3bf85dea074a4a","grayImgUrl":"https://community-static.tradeup.com/news/8c5460a7cc80dd22560efa26813d947d","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5300},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.96%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":8,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":833052794,"gmtCreate":1629191586118,"gmtModify":1676529960515,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"buy the dip","listText":"buy the dip","text":"buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833052794","repostId":"1147138826","repostType":4,"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892598142,"gmtCreate":1628670284686,"gmtModify":1676529815937,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"baidu ??","listText":"baidu ??","text":"baidu ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892598142","repostId":"2158475046","repostType":4,"isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892047738,"gmtCreate":1628618780924,"gmtModify":1676529799154,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good read","listText":"good read","text":"good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892047738","repostId":"1128779869","repostType":2,"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898414772,"gmtCreate":1628517257696,"gmtModify":1703507423119,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"insane gain rate","listText":"insane gain rate","text":"insane gain rate","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898414772","repostId":"1135535489","repostType":4,"isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899579803,"gmtCreate":1628208365802,"gmtModify":1703503079047,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899579803","repostId":"2157451943","repostType":4,"isVote":1,"tweetType":1,"viewCount":503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675270,"gmtCreate":1628184088890,"gmtModify":1703502806555,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899675270","repostId":"2157430168","repostType":4,"repost":{"id":"2157430168","pubTimestamp":1628173962,"share":"https://ttm.financial/m/news/2157430168?lang=&edition=fundamental","pubTime":"2021-08-05 22:32","market":"us","language":"en","title":"Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer","url":"https://stock-news.laohu8.com/highlight/detail?id=2157430168","media":"Reuters","summary":"(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Ve","content":"<p>(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was accepted by Veoneer's board.</p>\n<p>U.S.-listed shares of Veoneer rose 21.7% in premarket trading as the stage was set for a bidding war. Neither Magna or Veoneer made any immediate comment.</p>\n<p>Demand has been on the rise for advanced driver assistance systems, known in the industry as ADAS, that add features ranging from collision warning to parking assist. Some systems collect data from cameras and radar to monitor surroundings, interpret the situation and take action.</p>\n<p>Qualcomm, apart from powering mobile phones, has been a chip supplier to carmakers for a decade and last year started its own line of ADAS systems called Snapdragon Ride.</p>\n<p>Earlier this year it signed a signed a collaboration deal with Veoneer to develop a software and chip platform for driver-assistance systems.</p>\n<p>While fully self-driving vehicles are years away, assisted-driving features, such as adaptive cruise control, are being fitted into new cars by most manufacturers.</p>\n<p>Qualcomm hopes to grow its automotive chips business by creating open and competitive platforms for automakers along with Veoneer.</p>\n<p>\"As the automotive industry continues to transform, it is becoming increasingly important for automakers to have a partner who develops horizontal platforms that drive innovation and enable competition,\" said Qualcomm CEO Cristiano Amon.</p>\n<p>Magna has a similar interest in buying Veoneer as it tries to compete with ADAS makers such as Aptiv, Bosch and Continental to capture a larger share of the booming business.</p>\n<p>The Canadian company had offered to buy rival Veoneer in July for about $3.8 billion in cash.</p>\n<p>(Reporting by Chavi Mehta in Bengaluru and Supantha Mukherjee in Stockholm; Editing by Krishna Chandra Eluri, Vinay Dwivedi, Elaine Hardcastle)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qualcomm tops Magna's bid with $4.6 billion offer for Veoneer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQualcomm tops Magna's bid with $4.6 billion offer for Veoneer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was ...</p>\n\n<a href=\"https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VNE":"Veoneer, Inc.","QCOM":"高通"},"source_url":"https://finance.yahoo.com/news/qualcomm-offers-buy-automotive-tech-131242676.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2157430168","content_text":"(Reuters) -Chipmaker Qualcomm Inc said on Thursday it had offered to buy Swedish auto parts maker Veoneer Inc for $4.6 billion, an 18.4% premium to a bid by Canada's Magna International Inc that was accepted by Veoneer's board.\nU.S.-listed shares of Veoneer rose 21.7% in premarket trading as the stage was set for a bidding war. Neither Magna or Veoneer made any immediate comment.\nDemand has been on the rise for advanced driver assistance systems, known in the industry as ADAS, that add features ranging from collision warning to parking assist. Some systems collect data from cameras and radar to monitor surroundings, interpret the situation and take action.\nQualcomm, apart from powering mobile phones, has been a chip supplier to carmakers for a decade and last year started its own line of ADAS systems called Snapdragon Ride.\nEarlier this year it signed a signed a collaboration deal with Veoneer to develop a software and chip platform for driver-assistance systems.\nWhile fully self-driving vehicles are years away, assisted-driving features, such as adaptive cruise control, are being fitted into new cars by most manufacturers.\nQualcomm hopes to grow its automotive chips business by creating open and competitive platforms for automakers along with Veoneer.\n\"As the automotive industry continues to transform, it is becoming increasingly important for automakers to have a partner who develops horizontal platforms that drive innovation and enable competition,\" said Qualcomm CEO Cristiano Amon.\nMagna has a similar interest in buying Veoneer as it tries to compete with ADAS makers such as Aptiv, Bosch and Continental to capture a larger share of the booming business.\nThe Canadian company had offered to buy rival Veoneer in July for about $3.8 billion in cash.\n(Reporting by Chavi Mehta in Bengaluru and Supantha Mukherjee in Stockholm; Editing by Krishna Chandra Eluri, Vinay Dwivedi, Elaine Hardcastle)","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675116,"gmtCreate":1628184062335,"gmtModify":1703502806394,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899675116","repostId":"1173170520","repostType":4,"isVote":1,"tweetType":1,"viewCount":303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899083119,"gmtCreate":1628142395531,"gmtModify":1703502015289,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"Chinese EV will still be the dominant player in China","listText":"Chinese EV will still be the dominant player in China","text":"Chinese EV will still be the dominant player in China","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899083119","repostId":"1169931259","repostType":4,"isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890914494,"gmtCreate":1628075687218,"gmtModify":1703500722108,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"informative","listText":"informative","text":"informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/890914494","repostId":"1140177077","repostType":4,"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166787126,"gmtCreate":1624025385065,"gmtModify":1703826940379,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586352028840306","authorIdStr":"3586352028840306"},"themes":[],"htmlText":"good recommendation","listText":"good recommendation","text":"good recommendation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166787126","repostId":"2144775875","repostType":4,"repost":{"id":"2144775875","pubTimestamp":1624024260,"share":"https://ttm.financial/m/news/2144775875?lang=&edition=fundamental","pubTime":"2021-06-18 21:51","market":"us","language":"en","title":"Next Market Crash: 2 Top Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2144775875","media":"Motley Fool","summary":"Don't wait to jump on this red-hot tech company and unstoppable dividend stock.","content":"<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.</p>\n<p>No matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.</p>\n<h2>1. <a href=\"https://laohu8.com/S/FB\">Facebook</a></h2>\n<p><b>Facebook</b> (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.</p>\n<p>Facebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.</p>\n<p>2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.</p>\n<p>Facebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.</p>\n<p>If you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.</p>\n<p>After nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, <a href=\"https://laohu8.com/S/AONE\">one</a> that can generate consistent growth and maximize your portfolio returns.</p>\n<h2>2. AbbVie</h2>\n<p>Healthcare stock <b>AbbVie</b> (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from <b>Abbott Laboratories </b>in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.</p>\n<p>Stocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.</p>\n<p>The biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.</p>\n<p>There's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.</p>\n<p>Case in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.</p>\n<p>It's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.</p>\n<p>AbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.</p>\n<p>If you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Next Market Crash: 2 Top Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNext Market Crash: 2 Top Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144775875","content_text":"The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.\nNo matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.\n1. Facebook\nFacebook (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.\nFacebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.\n2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.\nFacebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.\nIf you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.\nAfter nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, one that can generate consistent growth and maximize your portfolio returns.\n2. AbbVie\nHealthcare stock AbbVie (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.\nStocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.\nThe biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.\nThere's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.\nCase in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.\nIt's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.\nAbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.\nIf you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":899579803,"gmtCreate":1628208365802,"gmtModify":1703503079047,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899579803","repostId":"2157451943","repostType":4,"repost":{"id":"2157451943","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628205795,"share":"https://ttm.financial/m/news/2157451943?lang=&edition=fundamental","pubTime":"2021-08-06 07:23","market":"us","language":"en","title":"Toplines After Hours US Market on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2157451943","media":"Tiger Newspress","summary":"U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s","content":"<p>U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.</p>\n<p>At 7:20&nbsp;p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&amp;P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.<img src=\"https://static.tigerbbs.com/fa2a1e6921f0962bd65e976709b6688d\" tg-width=\"1125\" tg-height=\"410\" referrerpolicy=\"no-referrer\"></p>\n<h3><b>Stocks making the biggest moves after hours:</b></h3>\n<p><a href=\"https://laohu8.com/S/DRNA\">Dicerna Pharmaceuticals</a> 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).</p>\n<p><a href=\"https://laohu8.com/S/GRPN\">Groupon</a> 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.</p>\n<p><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a> 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.</p>\n<p><a href=\"https://laohu8.com/S/CSOD\">Cornerstone OnDemand</a> 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.</p>\n<p><a href=\"https://laohu8.com/S/RAMP\">LiveRamp Holdings, Inc.</a> 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.</p>\n<p><a href=\"https://laohu8.com/S/SYNA\">Synaptics</a> 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.</p>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> 9% LOWER; Delayed Submission for U.S. Vaccine Approval</p>\n<p><a href=\"https://laohu8.com/S/NET\">Cloudflare, Inc.</a> 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.</p>\n<p><a href=\"https://laohu8.com/S/EXPE\">Expedia</a> 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.</p>\n<p><a href=\"https://laohu8.com/S/QDEL\">Quidel</a> 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.</p>\n<p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.</p>\n<p><a href=\"https://laohu8.com/S/PLUG\">Plug Power</a> 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.</p>\n<p><a href=\"https://laohu8.com/S/Z\">Zillow</a> 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.</p>\n<p><a href=\"https://laohu8.com/S/MNST\">Monster Beverage</a> 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.</p>\n<p><a href=\"https://laohu8.com/S/AIG\">American International Group Inc</a> 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines After Hours US Market on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines After Hours US Market on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-06 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.</p>\n<p>At 7:20&nbsp;p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&amp;P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.<img src=\"https://static.tigerbbs.com/fa2a1e6921f0962bd65e976709b6688d\" tg-width=\"1125\" tg-height=\"410\" referrerpolicy=\"no-referrer\"></p>\n<h3><b>Stocks making the biggest moves after hours:</b></h3>\n<p><a href=\"https://laohu8.com/S/DRNA\">Dicerna Pharmaceuticals</a> 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).</p>\n<p><a href=\"https://laohu8.com/S/GRPN\">Groupon</a> 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.</p>\n<p><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a> 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.</p>\n<p><a href=\"https://laohu8.com/S/CSOD\">Cornerstone OnDemand</a> 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.</p>\n<p><a href=\"https://laohu8.com/S/RAMP\">LiveRamp Holdings, Inc.</a> 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.</p>\n<p><a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.</p>\n<p><a href=\"https://laohu8.com/S/SYNA\">Synaptics</a> 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.</p>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> 9% LOWER; Delayed Submission for U.S. Vaccine Approval</p>\n<p><a href=\"https://laohu8.com/S/NET\">Cloudflare, Inc.</a> 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.</p>\n<p><a href=\"https://laohu8.com/S/EXPE\">Expedia</a> 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.</p>\n<p><a href=\"https://laohu8.com/S/QDEL\">Quidel</a> 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.</p>\n<p><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.</p>\n<p><a href=\"https://laohu8.com/S/PLUG\">Plug Power</a> 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.</p>\n<p><a href=\"https://laohu8.com/S/Z\">Zillow</a> 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.</p>\n<p><a href=\"https://laohu8.com/S/MNST\">Monster Beverage</a> 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.</p>\n<p><a href=\"https://laohu8.com/S/AIG\">American International Group Inc</a> 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCUL":"Ocular Therapeutix","Z":"Zillow","ZNGA":"Zynga","CSOD":"Cornerstone OnDemand","CVNA":"Carvana Co.","AIG":"美国国际集团","RAMP":"LiveRamp Holdings, Inc.","NVAX":"诺瓦瓦克斯医药","GRPN":"GroupOn","SYNA":"Synaptics Incorporated","DRNA":"Dicerna Pharmaceuticals, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157451943","content_text":"U.S. stock index futures were little changed during overnight trading on Thursday, ahead of Friday’s highly anticipated jobs report.\nAt 7:20 p.m. ET, Dow e-minis were down 32 points, or 0.09%, S&P 500 e-minis were down 3.25 points, or 0.07%, and Nasdaq 100 e-minis were down 5.25 points, or 0.03%.\nStocks making the biggest moves after hours:\nDicerna Pharmaceuticals 24% LOWER; announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna’s lead GalXC™ RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2 (PH1 and PH2).\nGroupon 14.8% HIGHER; reported Q2 EPS of $0.33, $0.36 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $266 million versus the consensus estimate of $242.47 million. Groupon sees FY2021 revenue of $950-990 million, versus the consensus of $998.1 million.\nZynga 15.7% LOWER; reported Q2 EPS of $0.02, which may not compare to the analyst estimate of $0.09. Revenue for the quarter came in at $720 million versus the consensus estimate of $713.01 million. Entered into a definitive agreement toacquireStarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock.\nCornerstone OnDemand 13.2% HIGHER; entered into a definitive agreement to be acquired by Clearlake Capital Group, L.P. (together with certain of its affiliates, Clearlake), a leading private equity firm. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2 billion.\nLiveRamp Holdings, Inc. 12.2% HIGHER; reported Q1 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $119 million versus the consensus estimate of $112.03 million.\nCarvana Co. 9.5% HIGHER; reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.\nSynaptics 7.2% HIGHER; reported Q4 EPS of $2.18, $0.18 better than the analyst estimate of $2.00. Revenue for the quarter came in at $327.8 million versus the consensus estimate of $324.45 million. Synaptics sees Q1 2022 revenue of $355-385 million, versus the consensus of $349.05 million.\nNovavax 9% LOWER; Delayed Submission for U.S. Vaccine Approval\nCloudflare, Inc. 5.3% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $152.4 million versus the consensus estimate of $146.06 million. Cloudflare sees FY2021 EPS of ($0.11)-($0.12), versus the consensus of ($0.10). Cloudflare sees FY2021 revenue of $629-633 million, versus the consensus of $614.8 million.\nExpedia 5.2% LOWER; reported Q2 EPS of ($1.13), $0.48 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2 billion.\nQuidel 6.9% LOWER; reported Q2 EPS of $0.75, $0.71 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $176.6 million versus the consensus estimate of $194.5 million.\nVirgin Galactic 5.2% HIGHER; reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $380 thousand. Reopening Sales, with Prices Beginning at $450,000 Per Seat.\nPlug Power 7.9% HIGHER; reported Q2 EPS of ($0.18), $0.10 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $124.6 million versus the consensus estimate of $114.02 million.\nZillow 1.14% HIGHER; reported Q2 revenue of $1.3 billion versus the consensus estimate of $1.28 billion.\nOcular Therapeutix 4.52% LOWER; announced that Regeneron (NASDAQ:REGN) has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.\nMonster Beverage 1.69% HIGHER; reported Q2 EPS of $0.75, $0.07 better than the analyst estimate of $0.68. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.\nAmerican International Group Inc 2.96% HIGHER; reported Q2 EPS of $1.52, $0.35 better than the analyst estimate of $1.17.","news_type":1},"isVote":1,"tweetType":1,"viewCount":503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892598142,"gmtCreate":1628670284686,"gmtModify":1676529815937,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"baidu ??","listText":"baidu ??","text":"baidu ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892598142","repostId":"2158475046","repostType":4,"repost":{"id":"2158475046","pubTimestamp":1628600400,"share":"https://ttm.financial/m/news/2158475046?lang=&edition=fundamental","pubTime":"2021-08-10 21:00","market":"us","language":"en","title":"5 Growth Stocks With 110% to 393% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2158475046","media":"Motley Fool","summary":"Analysts are calling for significant gains in these fast-paced stocks.","content":"<p>For the past nine months, the stock market has been practically unstoppable. The benchmark <b>S&amp;P 500</b> hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.</p>\n<p>But despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.</p>\n<h2>Coinbase Global: Implied upside of 152%</h2>\n<p>The first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem <b>Coinbase Global</b> (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million.&nbsp; Growing institutional interest in digital currencies like <b>Bitcoin</b>&nbsp;and <b>Ethereum</b>, along with rapidly rising prices for the Big <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> in crypto, drove investors to the platform.</p>\n<p>On the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big <a href=\"https://laohu8.com/S/TWOA\">Two</a> digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.</p>\n<p>Long story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.</p>\n<h2>Cresco Labs: Implied upside of 160%</h2>\n<p>One industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for <b>Cresco Labs</b> (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.</p>\n<p>Like other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.</p>\n<p>From a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.</p>\n<p>Cresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.</p>\n<h2>Baidu: Implied upside of 141%</h2>\n<p>In spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant <b>Baidu</b> (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.</p>\n<p>The most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months.&nbsp; Just as advertisers line up for placement on <b>Alphabet</b>'s leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.</p>\n<p>Beyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%.&nbsp; What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.</p>\n<p>While I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.</p>\n<h2><a href=\"https://laohu8.com/S/ICPT\">Intercept Pharmaceuticals</a>: Implied upside of 393%</h2>\n<p>If you're looking for a company with make-or-break opportunity, biotech stock <b>Intercept Pharmaceuticals</b> (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.</p>\n<p>The promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.</p>\n<p>Ultimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.</p>\n<p>The other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year.&nbsp; With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.</p>\n<p><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.</p>\n<h2>Nio: Implied upside of 110%</h2>\n<p>A fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.</p>\n<p>The excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.</p>\n<p>Having resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period.&nbsp; Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.</p>\n<p>Additionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.</p>\n<p>A $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Growth Stocks With 110% to 393% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Growth Stocks With 110% to 393% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","NIO":"蔚来","ICPT":"Intercept Pharmaceuticals","CRLBF":"Cresco Labs Inc.","COIN":"Coinbase Global, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/5-growth-stocks-with-110-to-393-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158475046","content_text":"For the past nine months, the stock market has been practically unstoppable. The benchmark S&P 500 hasn't undergone a single 5% drop, and it's nearly doubled since hitting its bear-market low on March 23, 2020.\nBut despite this record-breaking rally, Wall Street still sees value in a number of high-growth stocks. Based on the highest price target issued by a Wall Street investment bank or analyst, the following five growth stocks are expected to return 110% to as much as 393% to shareholders.\nCoinbase Global: Implied upside of 152%\nThe first rapidly growing stock with abundant upside, at least according to investment firm D.A. Davidson, is cryptocurrency brokerage and ecosystem Coinbase Global (NASDAQ:COIN). If the lofty $650 price target set by D.A. Davidson comes to fruition, Coinbase would deliver gains of 152% to its shareholders, relative to where it closed this past weekend.\nOn one hand, revenue and profits have soared for Coinbase. Net revenue in the first quarter catapulted to $1.6 billion from $179 million in the year-ago period, with net income of $771 million, up from $32 million.  Growing institutional interest in digital currencies like Bitcoin and Ethereum, along with rapidly rising prices for the Big Two in crypto, drove investors to the platform.\nOn the other hand, the Coinbase operating model has virtually no barriers to entry, and its trading fees are at risk of constantly being undercut by other cryptocurrency exchanges. Additionally, instead of thriving off of innovation, Coinbase is effectively held hostage by external interest in Bitcoin and Ethereum and the price performance of the Big Two digital currencies. When Bitcoin declined by 80% following its late 2017 peak, Coinbase's revenue was nearly halved.\nLong story short, while sales growth has been impressive, Coinbase isn't charting its own path to success. Its reliance on external factors makes $650 a target that's unlikely to be reached.\nCresco Labs: Implied upside of 160%\nOne industry where you'll find no shortage of aggressive price targets is cannabis -- specifically the U.S. pot industry. If the highest price target assigned by Wall Street of nearly $29 for Cresco Labs (OTC:CRLBF) proves accurate, investors in this marijuana stock could enjoy upside of 160%. And unlike Coinbase, this is a price target that I believe can eventually be achieved.\nLike other multistate operators, Cresco is expanding its retail operations organically and via acquisition. In June, it opened its 33rd dispensary nationally, and it holds enough retail licenses in its back pocket to eventually have closer to four dozen operating dispensaries.\nFrom a retail perspective, Cresco appears to be focusing its efforts on high-dollar states, as well as those that issue licenses on a limited basis (e.g., Illinois, Ohio, and Pennsylvania). The advantage of limited-license states is they're purposefully reining in competition. That means Cresco will have a genuine opportunity to build up its brands in key markets without the fear of being overrun by a multistate operator with deeper pockets.\nCresco is also the cannabis industry's leading wholesaler of weed. Even though wholesale cannabis produces weaker margins than retail, Cresco Labs has more than enough volume to make up for it. That's because it holds one of only a handful of cannabis distribution licenses in California. This license gives the company access to more than 575 dispensaries throughout the Golden State.\nBaidu: Implied upside of 141%\nIn spite of a recent crackdown by the Chinese government on a host of tech stocks, Wall Street remains largely undeterred that China-based internet search giant Baidu (NASDAQ:BIDU) will head higher. In fact, based on the high-water analyst price target of nearly $395, Baidu could offer gains of as much as 141%.\nThe most obvious catalyst for Baidu is its domestically dominant internet search engine. According to GlobalStats, Baidu has controlled between 66.9% and 79.9% of all internet search share in China over the trailing 12 months.  Just as advertisers line up for placement on Alphabet's leading internet search engine Google, they're willing to pay big bucks to reach internet users in China.\nBeyond the sustainable double-digit sales growth potential of internet search, Baidu is seeing exceptional early returns from its investment in cloud services and artificial intelligence (AI). Though these ancillary operations only accounted for 21% of first-quarter sales, revenue jumped by 70%.  What's more, cloud services and AI offer higher margins, relative to marketing revenue. Over time, we should see these ancillary segments really boost Baidu's cash flow generation.\nWhile I wouldn't count on $395 anytime soon, I do believe $395 is a reasonable future price target for the fast-growing Baidu.\nIntercept Pharmaceuticals: Implied upside of 393%\nIf you're looking for a company with make-or-break opportunity, biotech stock Intercept Pharmaceuticals (NASDAQ:ICPT) might be for you. This polarizing small-cap drug developer with a focus on therapies to treat liver diseases has price targets from Wall Street ranging from as low as $16 to as high as $82. If this upper target comes to fruition, shareholders would nearly quintuple their money.\nThe promise and peril for Intercept lies with obeticholic acid (OCA), an experimental treatment for nonalcoholic steatohepatitis (NASH), which affects between 2% and 5% of adults in this country and has no cure. In one respect, OCA met one of its two co-primary endpoints in the phase 3 Regenerate study -- a statistically significant improvement in fibrosis without a worsening of NASH. However, the highest and most-effective dose also led to a large number of cases of pruritus (itching) in trial participants.\nUltimately, Intercept's top drug candidate received a Complete Response Letter from the Food and Drug Administration. The plan for Intercept is to provide additional safety and trial data, with the goal of resubmitting the application. Even if OCA is approved and targeted at a small subset of the sickest patients, it could offer blockbuster sales potential in this untapped indication.\nThe other consideration here is Ocaliva (the brand-name version of OCA) is already approved to treat primary biliary cholangitis and is on track to bring in $325 million to $340 million in sales this year.  With an existing safety profile and a modestly growing sales floor, Intercept's risk/reward ratio looks favorable.\n\nThe all-electric Nio EC6 crossover hit showrooms last year. Image source: Nio.\nNio: Implied upside of 110%\nA fifth and final growth stock with serious upside, according to Wall Street, is China-based electric vehicle (EV) manufacturer Nio (NYSE:NIO). If the loftiest price target of more than $92 were to come true, investors would see their shares more than double in value.\nThe excitement surrounding Nio has to do with the impending electrification of China's automobiles. The Society of Automotive Engineers of China predicted back in 2018 that half of all vehicles sold in the world's largest auto market would run on alternative energy by 2035. With the EV industry predominantly nascent in China, the door is wide open for multiple companies to gobble up significant share.\nHaving resolved any funding concerns with capital raises, the focus now is on Nio's production expansion. Even facing industrywide chip shortages, Nio still managed to deliver almost 21,900 EVs during the second quarter, which was more than double what it delivered in the year-ago period.  Assuming chip supply issues can be resolved somewhat soon, Nio's annual EV run-rate output should climb toward 150,000.\nAdditionally, Nio is enticing new buyers with its battery-as-a-service program. Enrolling in this monthly fee-based program can lop thousands of dollars off the initial purchase price of a vehicle, all while improving buyer loyalty for Nio.\nA $92 price target might be a bit much for a company that's produced fewer than 118,000 EVs inception. Nevertheless, its execution of late is commendable.","news_type":1},"isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675270,"gmtCreate":1628184088890,"gmtModify":1703502806555,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899675270","repostId":"2157430168","repostType":4,"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890914494,"gmtCreate":1628075687218,"gmtModify":1703500722108,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"informative","listText":"informative","text":"informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/890914494","repostId":"1140177077","repostType":4,"repost":{"id":"1140177077","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628075003,"share":"https://ttm.financial/m/news/1140177077?lang=&edition=fundamental","pubTime":"2021-08-04 19:03","market":"us","language":"en","title":"Is Metaverse the future of Facebook?","url":"https://stock-news.laohu8.com/highlight/detail?id=1140177077","media":"Tiger Newspress","summary":"Last Wednesday, Facebook Inc topped Wall Street estimates both for second-quarter earnings and reven","content":"<p>Last Wednesday, Facebook Inc topped Wall Street estimates both for second-quarter earnings and revenue. However, shares went south as much as 5% in extended trading due to guidance of slowing revenue growth.</p>\n<p>Figure-wise, adjusted earnings amounted to $3.61 per share, exceeding $3.03 per share expected by Refinitiv-gathered analysts. Revenue grew by 56% YoY to $29.08 billion, also exceeding $27.89 billion, accelerating from a 48% increase in the prior quarter. It is Facebook's fastest growth since 2016.</p>\n<p>In the first financial period to really reflect a return to quasi-economic normalcy after a very online pandemic year, Facebook met user growth expectations. At the end of March, Facebook boasted 2.85 billion monthly active users across its network of apps. At the end of its second quarter, Facebook reported 2.9 billion monthly active users, roughly what was expected.</p>\n<p>In spite of a strong quarter, Facebook is warning of change ahead — namely impacts to its massive ad business, which generated $28.5 billion out of the company’s $29 billion this quarter. The company specifically named privacy-focused updates to Apple’s mobile operating system as a threat to its business.</p>\n<p>“We continue to expect increased ad targeting headwinds in 2021 from regulatory and platform changes, notably the recent iOS updates, which we expect to have a greater impact in the third quarter compared to the second quarter,” the company stated its investor report outlook.</p>\n<h4>Q2 user growth disappoints</h4>\n<p>Let's start with the key highlights from Q2 that turned investor sentiment south. For the past several quarters, now, Facebook has been dealing with a slowdown in user growth in the post-pandemic era. That trend played out even more strongly in Q2. Take a look at the DAU and MAU charts below:</p>\n<p><img src=\"https://static.tigerbbs.com/693a825137c8cd10e400eec68b3e7bf9\" tg-width=\"554\" tg-height=\"370\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/216eccd4ce8127278f911f6310913ecd\" tg-width=\"554\" tg-height=\"372\" referrerpolicy=\"no-referrer\"></p>\n<p>A summary of the above:</p>\n<ul>\n <li>DAUs at 1.908 billion, growing 1.6% sequentially and 6.9% y/y</li>\n <li>MAUs at 2.895 billion, growing 1.5% sequentially and 7.2% y/y</li>\n</ul>\n<p>We note that the y/y growth rates in MAUs were significantly compressed from Q1's pace of 9.6% y/y MAU growth.</p>\n<p>These trends are telling us something we already knew instinctively: Facebook benefited tremendously in 2020 due to the pandemic. DAUs, in particular, and average time spent on the app per user (not a metric that Facebook reports, but something that drives ARPU) jolted upward as users had little alternatives in the lockdown world to compete with digital entertainment and distraction.</p>\n<p>But picking apart at the geo-levels trends highlights additional concerns. Facebook has simply stopped growing in the U.S. and Canada. Its DAU and MAU counts in its home region have frozen at 185 million and 259 million, respectively. A North America user generates ~5x the ARPU of the worldwide index of Facebook users - so this slowdown will in particular hurt future growth.</p>\n<p>It's an even worse story in Europe, where DAU counts declined by 2 million sequentially and MAU counts declined by 3 million. Europe has been a little laxer in reopenings than the U.S., with many tourist hotspots reopening (especially for inter-EU travel), and we saw the effects of a more opened Europe summer season on Facebook's Q2 user counts in the region (potentially a harbinger of what will happen in the U.S. when it reopens more broadly). Seeing as Europe is Facebook's second-most lucrative region after North America, this is another concern.</p>\n<p>In Q2, Facebook generated 56% y/y revenue growth to $29.08 billion, beating Wall Street's expectations of $27.89 billion (+49% y/y) by a respectable seven-point margin. Yet the majority of this revenue growth was driven by ARPU growth, and in particular ad pricing. As investors who were active in tech stocks last year will recall, internet giants reported particular softness in ad pricing last year (Q2 and Q3 especially) as consumer brands pulled back on their marketing spend to conserve cash. This year, as pent-up consumer demand is racing to buy everything from cars to Peloton ad spend is up furiously. Globally, Facebook's ARPU is up 43%5 y/y to $10.12; in the U.S., ARPU is up an even stronger 45% y/y to $53.01:</p>\n<p>Yet this to be a temporary growth driver, as ad pricing can't continue expanding indefinitely. We note as well that declining amounts of time spent in the Facebook family of apps will also cause downward pressure on ARPU.</p>\n<p>Over the long run, Facebook must continue growing its core U.S. user base or start getting its Asia-Pacific and Rest of World users to a higher ARPU. Yet given that, for example, Asia users' $4.16 ARPU is already less than a tenth of the U.S. and also growing slower at 39% y/y in Q2, this may take a long time to equalize (if it ever will at all).</p>\n<h4>Metaverse</h4>\n<p>Mark Zuckerberg spent much of the company's earnings call revealing his vision for the company's transformation from social media to a metaverse: a digital world that Facebook is investing billions of dollars to create.</p>\n<p>The metaverse was first coined in the 1992 science fiction novel \"Snow Crash\" by Neal Stephenson. The term represents a meeting of the physical world with augmented and virtual reality.</p>\n<p>Zuckerberg called the metaverse the “next generation of the internet and next chapter for us as a company,” one that he said will create “entirely new experiences and economic opportunities.”</p>\n<p>He believes the metaverse will be the successor to the mobile internet, and creating this product group is the next step in Facebook's journey. He describes it as \"an embodied internet where instead of just viewing content -- you are in it.\" Facebook has invested heavily in virtual reality, spending $2 billion on acquiring Oculus, which develops its VR products and continues spending billions each year in R&amp;D.</p>\n<p>Zuckerberg thinks that many focus on the gaming side of things for the metaverse and highlights the growing entertainment sector of the market. Ultimately, Zuckerberg sees the metaverse as a hybrid of existing social platforms we have today — with the difference being the environment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Metaverse the future of Facebook?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Metaverse the future of Facebook?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-04 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Last Wednesday, Facebook Inc topped Wall Street estimates both for second-quarter earnings and revenue. However, shares went south as much as 5% in extended trading due to guidance of slowing revenue growth.</p>\n<p>Figure-wise, adjusted earnings amounted to $3.61 per share, exceeding $3.03 per share expected by Refinitiv-gathered analysts. Revenue grew by 56% YoY to $29.08 billion, also exceeding $27.89 billion, accelerating from a 48% increase in the prior quarter. It is Facebook's fastest growth since 2016.</p>\n<p>In the first financial period to really reflect a return to quasi-economic normalcy after a very online pandemic year, Facebook met user growth expectations. At the end of March, Facebook boasted 2.85 billion monthly active users across its network of apps. At the end of its second quarter, Facebook reported 2.9 billion monthly active users, roughly what was expected.</p>\n<p>In spite of a strong quarter, Facebook is warning of change ahead — namely impacts to its massive ad business, which generated $28.5 billion out of the company’s $29 billion this quarter. The company specifically named privacy-focused updates to Apple’s mobile operating system as a threat to its business.</p>\n<p>“We continue to expect increased ad targeting headwinds in 2021 from regulatory and platform changes, notably the recent iOS updates, which we expect to have a greater impact in the third quarter compared to the second quarter,” the company stated its investor report outlook.</p>\n<h4>Q2 user growth disappoints</h4>\n<p>Let's start with the key highlights from Q2 that turned investor sentiment south. For the past several quarters, now, Facebook has been dealing with a slowdown in user growth in the post-pandemic era. That trend played out even more strongly in Q2. Take a look at the DAU and MAU charts below:</p>\n<p><img src=\"https://static.tigerbbs.com/693a825137c8cd10e400eec68b3e7bf9\" tg-width=\"554\" tg-height=\"370\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/216eccd4ce8127278f911f6310913ecd\" tg-width=\"554\" tg-height=\"372\" referrerpolicy=\"no-referrer\"></p>\n<p>A summary of the above:</p>\n<ul>\n <li>DAUs at 1.908 billion, growing 1.6% sequentially and 6.9% y/y</li>\n <li>MAUs at 2.895 billion, growing 1.5% sequentially and 7.2% y/y</li>\n</ul>\n<p>We note that the y/y growth rates in MAUs were significantly compressed from Q1's pace of 9.6% y/y MAU growth.</p>\n<p>These trends are telling us something we already knew instinctively: Facebook benefited tremendously in 2020 due to the pandemic. DAUs, in particular, and average time spent on the app per user (not a metric that Facebook reports, but something that drives ARPU) jolted upward as users had little alternatives in the lockdown world to compete with digital entertainment and distraction.</p>\n<p>But picking apart at the geo-levels trends highlights additional concerns. Facebook has simply stopped growing in the U.S. and Canada. Its DAU and MAU counts in its home region have frozen at 185 million and 259 million, respectively. A North America user generates ~5x the ARPU of the worldwide index of Facebook users - so this slowdown will in particular hurt future growth.</p>\n<p>It's an even worse story in Europe, where DAU counts declined by 2 million sequentially and MAU counts declined by 3 million. Europe has been a little laxer in reopenings than the U.S., with many tourist hotspots reopening (especially for inter-EU travel), and we saw the effects of a more opened Europe summer season on Facebook's Q2 user counts in the region (potentially a harbinger of what will happen in the U.S. when it reopens more broadly). Seeing as Europe is Facebook's second-most lucrative region after North America, this is another concern.</p>\n<p>In Q2, Facebook generated 56% y/y revenue growth to $29.08 billion, beating Wall Street's expectations of $27.89 billion (+49% y/y) by a respectable seven-point margin. Yet the majority of this revenue growth was driven by ARPU growth, and in particular ad pricing. As investors who were active in tech stocks last year will recall, internet giants reported particular softness in ad pricing last year (Q2 and Q3 especially) as consumer brands pulled back on their marketing spend to conserve cash. This year, as pent-up consumer demand is racing to buy everything from cars to Peloton ad spend is up furiously. Globally, Facebook's ARPU is up 43%5 y/y to $10.12; in the U.S., ARPU is up an even stronger 45% y/y to $53.01:</p>\n<p>Yet this to be a temporary growth driver, as ad pricing can't continue expanding indefinitely. We note as well that declining amounts of time spent in the Facebook family of apps will also cause downward pressure on ARPU.</p>\n<p>Over the long run, Facebook must continue growing its core U.S. user base or start getting its Asia-Pacific and Rest of World users to a higher ARPU. Yet given that, for example, Asia users' $4.16 ARPU is already less than a tenth of the U.S. and also growing slower at 39% y/y in Q2, this may take a long time to equalize (if it ever will at all).</p>\n<h4>Metaverse</h4>\n<p>Mark Zuckerberg spent much of the company's earnings call revealing his vision for the company's transformation from social media to a metaverse: a digital world that Facebook is investing billions of dollars to create.</p>\n<p>The metaverse was first coined in the 1992 science fiction novel \"Snow Crash\" by Neal Stephenson. The term represents a meeting of the physical world with augmented and virtual reality.</p>\n<p>Zuckerberg called the metaverse the “next generation of the internet and next chapter for us as a company,” one that he said will create “entirely new experiences and economic opportunities.”</p>\n<p>He believes the metaverse will be the successor to the mobile internet, and creating this product group is the next step in Facebook's journey. He describes it as \"an embodied internet where instead of just viewing content -- you are in it.\" Facebook has invested heavily in virtual reality, spending $2 billion on acquiring Oculus, which develops its VR products and continues spending billions each year in R&amp;D.</p>\n<p>Zuckerberg thinks that many focus on the gaming side of things for the metaverse and highlights the growing entertainment sector of the market. Ultimately, Zuckerberg sees the metaverse as a hybrid of existing social platforms we have today — with the difference being the environment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140177077","content_text":"Last Wednesday, Facebook Inc topped Wall Street estimates both for second-quarter earnings and revenue. However, shares went south as much as 5% in extended trading due to guidance of slowing revenue growth.\nFigure-wise, adjusted earnings amounted to $3.61 per share, exceeding $3.03 per share expected by Refinitiv-gathered analysts. Revenue grew by 56% YoY to $29.08 billion, also exceeding $27.89 billion, accelerating from a 48% increase in the prior quarter. It is Facebook's fastest growth since 2016.\nIn the first financial period to really reflect a return to quasi-economic normalcy after a very online pandemic year, Facebook met user growth expectations. At the end of March, Facebook boasted 2.85 billion monthly active users across its network of apps. At the end of its second quarter, Facebook reported 2.9 billion monthly active users, roughly what was expected.\nIn spite of a strong quarter, Facebook is warning of change ahead — namely impacts to its massive ad business, which generated $28.5 billion out of the company’s $29 billion this quarter. The company specifically named privacy-focused updates to Apple’s mobile operating system as a threat to its business.\n“We continue to expect increased ad targeting headwinds in 2021 from regulatory and platform changes, notably the recent iOS updates, which we expect to have a greater impact in the third quarter compared to the second quarter,” the company stated its investor report outlook.\nQ2 user growth disappoints\nLet's start with the key highlights from Q2 that turned investor sentiment south. For the past several quarters, now, Facebook has been dealing with a slowdown in user growth in the post-pandemic era. That trend played out even more strongly in Q2. Take a look at the DAU and MAU charts below:\n\nA summary of the above:\n\nDAUs at 1.908 billion, growing 1.6% sequentially and 6.9% y/y\nMAUs at 2.895 billion, growing 1.5% sequentially and 7.2% y/y\n\nWe note that the y/y growth rates in MAUs were significantly compressed from Q1's pace of 9.6% y/y MAU growth.\nThese trends are telling us something we already knew instinctively: Facebook benefited tremendously in 2020 due to the pandemic. DAUs, in particular, and average time spent on the app per user (not a metric that Facebook reports, but something that drives ARPU) jolted upward as users had little alternatives in the lockdown world to compete with digital entertainment and distraction.\nBut picking apart at the geo-levels trends highlights additional concerns. Facebook has simply stopped growing in the U.S. and Canada. Its DAU and MAU counts in its home region have frozen at 185 million and 259 million, respectively. A North America user generates ~5x the ARPU of the worldwide index of Facebook users - so this slowdown will in particular hurt future growth.\nIt's an even worse story in Europe, where DAU counts declined by 2 million sequentially and MAU counts declined by 3 million. Europe has been a little laxer in reopenings than the U.S., with many tourist hotspots reopening (especially for inter-EU travel), and we saw the effects of a more opened Europe summer season on Facebook's Q2 user counts in the region (potentially a harbinger of what will happen in the U.S. when it reopens more broadly). Seeing as Europe is Facebook's second-most lucrative region after North America, this is another concern.\nIn Q2, Facebook generated 56% y/y revenue growth to $29.08 billion, beating Wall Street's expectations of $27.89 billion (+49% y/y) by a respectable seven-point margin. Yet the majority of this revenue growth was driven by ARPU growth, and in particular ad pricing. As investors who were active in tech stocks last year will recall, internet giants reported particular softness in ad pricing last year (Q2 and Q3 especially) as consumer brands pulled back on their marketing spend to conserve cash. This year, as pent-up consumer demand is racing to buy everything from cars to Peloton ad spend is up furiously. Globally, Facebook's ARPU is up 43%5 y/y to $10.12; in the U.S., ARPU is up an even stronger 45% y/y to $53.01:\nYet this to be a temporary growth driver, as ad pricing can't continue expanding indefinitely. We note as well that declining amounts of time spent in the Facebook family of apps will also cause downward pressure on ARPU.\nOver the long run, Facebook must continue growing its core U.S. user base or start getting its Asia-Pacific and Rest of World users to a higher ARPU. Yet given that, for example, Asia users' $4.16 ARPU is already less than a tenth of the U.S. and also growing slower at 39% y/y in Q2, this may take a long time to equalize (if it ever will at all).\nMetaverse\nMark Zuckerberg spent much of the company's earnings call revealing his vision for the company's transformation from social media to a metaverse: a digital world that Facebook is investing billions of dollars to create.\nThe metaverse was first coined in the 1992 science fiction novel \"Snow Crash\" by Neal Stephenson. The term represents a meeting of the physical world with augmented and virtual reality.\nZuckerberg called the metaverse the “next generation of the internet and next chapter for us as a company,” one that he said will create “entirely new experiences and economic opportunities.”\nHe believes the metaverse will be the successor to the mobile internet, and creating this product group is the next step in Facebook's journey. He describes it as \"an embodied internet where instead of just viewing content -- you are in it.\" Facebook has invested heavily in virtual reality, spending $2 billion on acquiring Oculus, which develops its VR products and continues spending billions each year in R&D.\nZuckerberg thinks that many focus on the gaming side of things for the metaverse and highlights the growing entertainment sector of the market. Ultimately, Zuckerberg sees the metaverse as a hybrid of existing social platforms we have today — with the difference being the environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833052794,"gmtCreate":1629191586118,"gmtModify":1676529960515,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"buy the dip","listText":"buy the dip","text":"buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833052794","repostId":"1147138826","repostType":4,"repost":{"id":"1147138826","pubTimestamp":1629179191,"share":"https://ttm.financial/m/news/1147138826?lang=&edition=fundamental","pubTime":"2021-08-17 13:46","market":"hk","language":"en","title":"China tech stocks lower as nation issues draft competition rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1147138826","media":"Bloomberg","summary":"The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules ban","content":"<p>The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator&nbsp;released&nbsp;draft rules banning unfair competition among the nation’s online platform operators.</p>\n<p>Baidu Inc.&nbsp;and&nbsp;NetEase Inc.&nbsp;slumped as much as 5% while&nbsp;Tencent Holdings Ltd.&nbsp;and Alibaba Group Holding Ltd. slid more than 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/941afd804b1d8567636a57f81beca1e6\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"></p>\n<p>The wide-ranging proposals released Tuesday come after the tech-industry ministry launched a campaign last month aimed at rooting out a raft of&nbsp;problematic&nbsp;behavior.</p>\n<p>The draft covers protections for intellectual property and brand reputation as well as a ban against using algorithms or fake reviews to promote goods and services. Alongside expressly prohibited behaviors like forced exclusivity arrangements, companies will also not be permitted to use technical means to interfere with the operations of rival platforms or maliciously render those services incompatible with their own.</p>\n<p>The latter could force giants like Tencent and Alibaba Group Holding Ltd. to dismantle their walled-off ecosystems that had prevented users from accessing one company’s services from the other’s platforms. Alibaba Chief Executive Officer Daniel Zhang earlier this month signaled support for the removal of those barriers, saying that he saw “cross-platform openness and connectivity as a positive trend.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China tech stocks lower as nation issues draft competition rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina tech stocks lower as nation issues draft competition rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-17 13:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.\nBaidu Inc. and NetEase Inc. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09618":"京东集团-SW","HSTECH":"恒生科技指数","09999":"网易-S","00700":"腾讯控股","09988":"阿里巴巴-W"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-17/technology-stocks-fall-as-china-issues-draft-competition-rules?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147138826","content_text":"The Hang Seng Tech Index dropped as much as 3%, as China’s market regulator released draft rules banning unfair competition among the nation’s online platform operators.\nBaidu Inc. and NetEase Inc. slumped as much as 5% while Tencent Holdings Ltd. and Alibaba Group Holding Ltd. slid more than 4%.\n\nThe wide-ranging proposals released Tuesday come after the tech-industry ministry launched a campaign last month aimed at rooting out a raft of problematic behavior.\nThe draft covers protections for intellectual property and brand reputation as well as a ban against using algorithms or fake reviews to promote goods and services. Alongside expressly prohibited behaviors like forced exclusivity arrangements, companies will also not be permitted to use technical means to interfere with the operations of rival platforms or maliciously render those services incompatible with their own.\nThe latter could force giants like Tencent and Alibaba Group Holding Ltd. to dismantle their walled-off ecosystems that had prevented users from accessing one company’s services from the other’s platforms. Alibaba Chief Executive Officer Daniel Zhang earlier this month signaled support for the removal of those barriers, saying that he saw “cross-platform openness and connectivity as a positive trend.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898414772,"gmtCreate":1628517257696,"gmtModify":1703507423119,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"insane gain rate","listText":"insane gain rate","text":"insane gain rate","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898414772","repostId":"1135535489","repostType":4,"isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166787126,"gmtCreate":1624025385065,"gmtModify":1703826940379,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"good recommendation","listText":"good recommendation","text":"good recommendation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166787126","repostId":"2144775875","repostType":4,"repost":{"id":"2144775875","pubTimestamp":1624024260,"share":"https://ttm.financial/m/news/2144775875?lang=&edition=fundamental","pubTime":"2021-06-18 21:51","market":"us","language":"en","title":"Next Market Crash: 2 Top Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2144775875","media":"Motley Fool","summary":"Don't wait to jump on this red-hot tech company and unstoppable dividend stock.","content":"<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.</p>\n<p>No matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.</p>\n<h2>1. <a href=\"https://laohu8.com/S/FB\">Facebook</a></h2>\n<p><b>Facebook</b> (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.</p>\n<p>Facebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.</p>\n<p>2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.</p>\n<p>Facebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.</p>\n<p>If you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.</p>\n<p>After nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, <a href=\"https://laohu8.com/S/AONE\">one</a> that can generate consistent growth and maximize your portfolio returns.</p>\n<h2>2. AbbVie</h2>\n<p>Healthcare stock <b>AbbVie</b> (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from <b>Abbott Laboratories </b>in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.</p>\n<p>Stocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.</p>\n<p>The biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.</p>\n<p>There's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.</p>\n<p>Case in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.</p>\n<p>It's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.</p>\n<p>AbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.</p>\n<p>If you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Next Market Crash: 2 Top Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNext Market Crash: 2 Top Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144775875","content_text":"The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.\nNo matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.\n1. Facebook\nFacebook (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.\nFacebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.\n2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.\nFacebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.\nIf you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.\nAfter nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, one that can generate consistent growth and maximize your portfolio returns.\n2. AbbVie\nHealthcare stock AbbVie (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.\nStocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.\nThe biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.\nThere's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.\nCase in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.\nIt's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.\nAbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.\nIf you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899675116,"gmtCreate":1628184062335,"gmtModify":1703502806394,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899675116","repostId":"1173170520","repostType":4,"isVote":1,"tweetType":1,"viewCount":303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899083119,"gmtCreate":1628142395531,"gmtModify":1703502015289,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"Chinese EV will still be the dominant player in China","listText":"Chinese EV will still be the dominant player in China","text":"Chinese EV will still be the dominant player in China","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899083119","repostId":"1169931259","repostType":4,"isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892047738,"gmtCreate":1628618780924,"gmtModify":1676529799154,"author":{"id":"3586352028840306","authorId":"3586352028840306","name":"greenyellow","avatar":"https://static.tigerbbs.com/1f0a92f7363aa0458159e4af71ec751b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586352028840306","idStr":"3586352028840306"},"themes":[],"htmlText":"good read","listText":"good read","text":"good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892047738","repostId":"1128779869","repostType":2,"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}